Phase 4 N=48 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
N/A N=115 Precision Diets for Diabetes Prevention
Pre Diabetes · Insulin Resistance · Diabetes Mellitus, Type 2
Primary: Change in Glycemic Control as Measured by Change Blood Sugar Values — 88.9; 95.4; 90.8; 96.7 mg/dL — p=<0.001
N/A N=19 Exogenous Ketones in Type 2 Diabetes
Ketosis · Type 2 Diabetes
Primary: Plasma Glucose — 7.3; 7.2; 6.2; 6.6 mmol/L
N/A N=95 Early Screening and Treatment of Women With Prediabetes in Pregnancy
Diabetes · Pregnancy
Primary: Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation. — 19; 23 Participants — p=0.32
Phase 2 N=29 The University of Michigan PCOS Intervention Using Nutritional Ketosis
Polycystic Ovary Syndrome
Primary: Mean Percent Body Weight Loss — -7.67 percentage of weight — p=<.001
N/A N=73 Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States
Malnutrition; Diabetes · Diabetes
Primary: Endogenous Glucose Production — 0.5; 0.84; 0.6; 0.4 mg/kg/min
N/A N=65 Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
Type 2 Diabetes Mellitus
Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05
N/A N=101 Role of Pancreatic Triglyceride Content in Beta-cell Function
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent
N/A N=30 Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Metabolic Syndrome · Diabetes Mellitus, Type 2 · Pre Diabetes
Primary: Hemoglobin A1c — -.42; -0.37; 0.02 % of hemoglobin — p=0.001
N/A N=157 Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
Diabetes Mellitus, Type 2
Primary: Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles — 1.76; 3.58; 2.14; 2.22 arbitrary units/ng rRNA — p=.001
N/A N=20 Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes
Prediabetic State
Primary: Plasma Ketone Concentrations — -52; 12; 493; 627 (µmol/h)/L
Phase 1 N=40 Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
Phase 4 N=21 Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
Diabetes Mellitus, Type 1
Primary: Capillary Blood Beta-hydroxybutyrate (BOHB) During Outpatient Care — 0.1; 0.2 mmol/L — p=< 0.0001
N/A N=70 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
Evaluate Ketogenic Stress
Primary: Change in Beta-hydroxybutyrate Levels in Blood — -0.23; 0.63; 0.24; 0.31 mM
Phase 4 N=24 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
N/A N=483 Presessions for the National Diabetes Prevention Program
Prediabetic State · Obesity · Gestational Diabetes
Primary: Weight Loss — 3.1; 2.8 % of weight loss
N/A N=88 Beta Cell Restoration Through Fat Mitigation
Prediabetes · Type 2 Diabetes · Obesity
Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05
Phase 3 N=66 Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Diabetes Prevention in Women After GDM Who Are at High-risk
Primary: Change in Body Weight — -21.5; -12.5; -4.4 kilograms — p=<0.032
Phase 1 N=21 Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Empaglifozin · Physiological Effects of Drugs · Hypoglycemic Agents
Primary: Change in Serum β-hydroxybutyrate (BHB) — 40.717 µM — p=<0.001
N/A N=43 Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Type 1 Diabetes
Primary: Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin — 0.08; 0.25; 0.21 mM
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=32 The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
Type 1 Diabetes
Primary: Energy Expenditure — 1978.3; 1969.8; 2414.8; 1497.7 Kilocalories — p=0.24
Phase 4 N=54 Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Gestational Diabetes · Diabetes, Gestational · Pregnancy in Diabetes
Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9
N/A N=507 Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=17 TRE With Physical Activity for Weight Management
Pre Diabetes · Overweight and Obesity
Primary: Body Weight Changes Between Week 1 to Week 10 — -2.1; -4.2; -1.3; .1 Percent body weight loss
N/A N=55 Eating Disorder Prevention Program for Women With T1D
Eating Disorders · Type 1 Diabetes
Primary: Percentage of Time With Blood Sugar in Range as a Measure of Glycemic Control — 0.61; 0.63 percentage of time
N/A N=10 PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis
Healthy
Primary: Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet — 0.672; 4.83 µmol/100g/min
N/A N=39 [11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Type2 Diabetes
Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875